Clinical Drug Investigation

, Volume 29, Issue 8, pp 551–555 | Cite as

Effects of Recombinant Human Granulocyte Colony-Stimulating Factor Filgrastim on ECG Parameters in Neutropenic Patients

A Single-Centre,Prospective Study
Short Communication


Background and objective: Human granulocyte colony-stimulating factor (G-CSF) is a haematopoietic hormone that promotes the growth, proliferation, differentiation and maturation of neutrophil precursors. Filgrastim is a recombinant human G-CSF. Myocardial infarction, atrial fibrillation and arrhythmia have been reported in several patients with malignancy receiving filgrastim, but a causal relationship with the drug has not been established. The purpose of this study was to investigate the changes in ECG parameters in neutropenic patients during treatment with filgrastim.

Methods: This was a single-centre, prospective study carried out in a hospital emergency room. Patients with neutropenia and malignancy who were required to receive filgrastim were eligible for the study. After a reference ECG had been obtained, filgrastim was administered to all patients at a dose of 5 µg/kg/day subcutaneously for 2 days. Follow-up ECGs were then obtained at 12-hourly intervals. Continuous telemetric monitoring was conducted throughout hospitalization.

Results: Serial ECG parameters were compared in 102 patients. There were no statistically significant differences between baseline and follow-up ECG measurements of rhythm, P-wave duration, PR interval, QRS-wave duration, corrected QT (QTc) interval, ECG axis, premature supraventricular events, ventricular arrhythmia, R-wave progression, right bundle branch block or left bundle branch block. There was a significant reduction in mean heart rate in subsequent ECGs compared with baseline (p≪0.05).

Conclusion: This study did not demonstrate any ECG changes other than a significant reduction in mean heart rate in this selected population of neutropenic patients given 2 days’ treatment with subcutaneous 5 µg/kg/day of filgrastim.


Febrile Neutropenia Filgrastim Left Bundle Branch Block Neutropenic Patient Right Bundle Branch Block 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Borleffs JC, Bosschaert M, Vrehen HM, et al. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther 1998; 20(4): 722–36PubMedCrossRefGoogle Scholar
  2. 2.
    Filgrastim. AHFS drug information [online]. Available from URL: a392033.htm [Accessed 2008 May 29]Google Scholar
  3. 3.
    Takahama H, Minamino T, Hirata A, et al. Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 2006; 20(3): 159–65PubMedCrossRefGoogle Scholar
  4. 4.
    Lee JJ, Chung IJ, Ahn YK, et al. Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection. Leukemia 2000; 14(7): 1324–5PubMedCrossRefGoogle Scholar
  5. 5.
    Trillet-Lenoir V, Manegold JGC, Von Pawel J, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–24PubMedCrossRefGoogle Scholar
  6. 6.
    Holmes FA, Jones SE, Shaughnessy JO. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903–9PubMedCrossRefGoogle Scholar
  7. 7.
    Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte-colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell-lung cancer. N Engl J Med 1991; 325: 164–70PubMedCrossRefGoogle Scholar
  8. 8.
    Lindemann A, Rumberger B. Vascular complications in patients treated with granulocyte colony-stimulating factor (G-CSF). Eur J Cancer 1993; 29A(16): 2338–9PubMedCrossRefGoogle Scholar
  9. 9.
    Kuroiwa M, Okamura T, Kanaji T, et al. Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol 1996; 63(4): 311–6PubMedCrossRefGoogle Scholar
  10. 10.
    Conti JA, Scher HI. Acute arterial thrombosis after escalated-dose methotrexate, vinblastin, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor: a possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer 1992; 70(11): 2699–702PubMedCrossRefGoogle Scholar
  11. 11.
    Kaptan K, Beyan C, Ifran A. Granulocyte colony-stimulating factor. CMAJ 2006; 175(9): 1095PubMedGoogle Scholar
  12. 12.
    Amgen. Neupogen® (filgrastim) [prescribing information]. Thousand Oaks (CA): Amgen, 2004 Dec 20Google Scholar
  13. 13.
    Raisch DW, Holdsworth MT, Winter SS, et al. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children. Value Health 2003; 6(2): 158–66PubMedCrossRefGoogle Scholar
  14. 14.
    Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern Med J 2007; 37(11): 760–6PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Ozlem Guneyse
    • 1
  • Ozge Ecmel Onur
    • 1
  • Arzu Denizbasi
    • 1
  1. 1.Department of Emergency MedicineMarmara University School of MedicineIstanbulTurkey

Personalised recommendations